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Abstract: Hepatitis C virus (HCV) is a Flavivirus with a positive-sense, single-stranded 
RNA genome of about 9,600 nucleotides. It is a major cause of liver disease, infecting 
almost 200 million people all over the world. Similarly to  most RNA viruses, HCV 
displays very high levels of genetic diversity which have been used to differentiate six 
major genotypes and about 80 subtypes. Although the different genotypes and subtypes 
share basic biological and pathogenic features they differ in clinical outcomes, response to 
treatment and epidemiology. The first HCV recombinant strain, in which different genome 
segments derived from parentals of different genotypes, was described in St. Petersburg 
(Russia) in 2002. Since then, there have been only a few more than a dozen reports 
including descriptions of HCV recombinants at all levels: between genotypes, between 
subtypes of the same genotype and even between strains of the same subtype. Here, we 
review the literature considering the reasons underlying the difficulties for unequivocally 
establishing recombination in this virus along with the analytical methods necessary to do 
it. Finally, we analyze the potential consequences, especially in clinical practice, of HCV 
recombination in light of the coming new therapeutic approaches against this virus. 
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1. Introduction 
Hepatitis C virus (HCV) infects about 170 million people worldwide, about 3% of the world’s 
population  [1]. Infection by HCV is the major cause of liver disease and a potential cause of 
substantial morbidity and mortality in the future [2]. Until the recent discovery of a canine relative [3], 
HCV was the only species of the genus Hepacivirus within the family Flaviviridae. It has a single 
stranded, positive-sense, non-segmented RNA genome of about 9,600 nucleotides (nt) and a single, 
long open reading frame encoding a polyprotein of about 3,000 amino acids with the gene order   
C-E1-E2-p7-NS2-NS3-NS4A-NS4B-NS5A-NS5B. In addition, alternative translation products 
(F protein) have been detected from a reading frame overlapping the core gene (core+1/ARFP) [4], but 
its biological role remains elusive. The structural proteins are C (core) and E1 and E2 (envelope 
glycoproteins). The p7 protein seems to be an ion channel [5]. The NS2 through NS5 regions encode 
the remaining non-structural proteins [6]; NS2 is a transmembrane protein; NS3 has a dual role as 
serine protease and RNA helicase; NS4A is a cofactor of NS3; NS4B is a membrane-associated protein; 
NS5A is a component of the replicase complex, and NS5B is the RNA-dependent RNA polymerase. 
Six major genotypes and about 80 subtypes of HCV have been described [7,8] based on levels of 
sequence divergence. HCV genotypes have been shown to be distributed over distinct geographical 
areas and although they share their most basic biological features, there seems to be some differences 
in their susceptibility to interferon (IFN)-based therapies [9,10]. Genotype 1 is the predominant variant 
in developed countries and shows the poorest response to therapy. Although with a lower frequency, 
infections with HCV genotypes 2 and 3 are also common in Europe, and show the best response rates 
to IFN-based therapies.  
HCV is mainly transmitted by parenteral routes and differences in their transmission rates can be an 
important factor to explain the differences in prevalence of a genotype/subtype in different geographic 
regions [11–13]. Needle sharing among intravenous drug users (IDUs) currently represents the most 
common route of acquisition of HCV in the developed world [14].  Because HCV and human 
immunodeficiency virus (HIV) share blood-borne transmission routes, HIV/HCV co-infection is 
relatively frequent, especially in countries such as Spain and Italy, with a high prevalence of HCV/HIV 
infection due to injecting drug use [15].  
Like HIV-1, HCV is characterized by high levels of genetic heterogeneity [16,17] which impact 
heavily on different aspects such as viral persistence, susceptibility to treatment, and disease 
progression, and lack of an efficient vaccine, among others  [18–20]. As for other RNA viruses, 
mutation at the nucleotide level seems to be the primary cause of genetic variation in HCV, due to the 
use of an error-prone, non-proofreading RNA-dependent RNA-polymerase for replication of its 
genetic material. The mutation rate of HCV, estimated at 10
−4 substitutions per site and round of 
copying [21], is among the highest for RNA viruses including retroviruses [22], and would seem to be 
high enough to generate all the genetic variation found in this virus. Alternative mechanisms for 
generating genetic variability in viruses, such as reassortment, cannot operate in HCV, because it has a 
non-segmented genome, or act very sparingly, such as the introduction of indels [23]. 
An additional mechanism generating genetic variation in viruses is recombination. Although 
recombination is usually important in most RNA viruses, until recently the evidence for recombination 
in HCV was scarce  [24], suggesting that these events are rare in vivo  and that the resulting Viruses 2011, 3 
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recombinants are usually not viable [25]. However, in the last few years, a few natural inter-genotype, 
intra-genotype (inter-subtype) and even intra-strain recombinants of HCV have been identified, 
changing previous ideas about the absence of recombination in this virus. This view was based on two 
main reasons. On the one hand, until 2002 not a single, convincing case of a well characterized HCV 
recombinant had been identified [26]. Additionally, experimental evidence suggested that 
superinfection by another HCV isolate was prevented in HCV-infected cells [27]. Given that for viral 
recombination to occur it is necessary that two different viruses infect the same cell simultaneously, 
the impossibility of superinfection also prevented the appearance of recombinant viruses.  
Here, we review the evidence for recombination in HCV and analyze why it is so difficult to detect 
it. Additionally, we consider how to obtain convincing evidence of recombination and its possible 
consequences, both at the evolutionary and clinical levels. 
2. Reports of Recombination in HCV 
The first convincing report of an HCV recombinant strain was published in 2002 by Kalinina et al. [26]. 
Some earlier reports had already described “chimeric” strains in which partial sequences for different 
regions in the viral genome led to discordant genotyping of two isolates from Honduras [24], with the 
5'-end (at least portions of the core and E2 and p7 genes) corresponding to subtype 1a and the 3'-end 
(NS5 gene) to subtype 3a. As no further sequencing was possible for these isolates, it was not possible 
to determine their exact points of recombination and whether they represented one or two different 
recombination events. 
As indicated above, the first bona-fide recombinant strain of HCV was obtained in St. Petersburg 
(Russia) in 2002 [26]. These authors identified an intergenotype recombinant between a subtype 2k 
and a subtype 1b. The recombination breakpoint was mapped to the NS2 gene, around position 3,175. 
Subsequently, the full genome sequence of this isolate was determined [28] and the initial breakpoint 
was confirmed. This led to the proposal of a new strain designation as RF1_2k/1b, in analogy to the 
nomenclature used for recombinant circulating forms of HIV. The authors identified two hairpin 
structures, denoted HS1 and HS2, in the vicinity of the proposed recombination breakpoint in the 
parental strains which were absent from the recombinant form. From this observation, they proposed a 
molecular mechanism for recombination in HCV consisting of template switching during the synthesis 
of the negative strand facilitated by the binding of HS2 to the RNA-dependent RNA polymerase which 
enabled 3'-terminal extension during recombination. 
One important feature of this first report is that it documented not one but six different isolates, all 
derived from the same recombination event. This indicated that the recombinant strain was circulating 
in the population (all the isolates were obtained in a molecular epidemiology survey of HCV in 
St. Petersburg) and its origin was dated at least 10  years before the date of isolation. This same 
recombinant strain has been isolated in other countries (Ireland [29], Uzbekistan [30], Cyprus [31] and 
Georgia or France [32]) thus indicating that, even if it is not favored by natural selection, it is at least 
not selected against. This has important consequences for our understanding of the integration of 
different components of the HCV genome and proteome even after substantial divergence (the average 
genetic distance between different HCV genotypes is around 0.40 substitutions per site). Viruses 2011, 3 
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In addition to RF1_2k/1b, at least eight different intergenotypic recombinant forms (RFs) of HCV 
have been described and totally or partially characterized (Table 1). All HCV genotypes except for 
genotype 4 have been found in RFs and they have a wide geographic distribution. Interestingly, all RFs 
but one (RF_3a/1b, [33]) are formed by a 5'-end of genotype 2 and 3'-end of a different genotype, in 
which only subtype 1b appears in more than one RF. Given that some subtypes of genotype 2 and 
subtype 1b are usually found in older patients and not usually related to the relatively recent epidemic 
spread linked to increased usage of intravenous drugs [2], at present it is not possible to ascertain 
whether this pattern derives from adaptive features or is simply due to chance. 
One seemingly common feature of intergenotypic RFs of HCV is that their breakpoints have been 
mapped to either gene NS2 or NS3, with a high proportion of them falling in a small range between 
amino acids 1,022 and 1,042. Although no detailed analysis of RNA secondary structure in the vicinity 
of this region has been reported so far, the small stretch of the HCV genome involved in recombination 
might be explained by a similar mechanism to that proposed for RF1_2k/1b [28], as detailed above. 
HCV intersubtype divergence at the nucleotide level usually ranges between 0.2 and 0.3 
substitutions/site. In consequence, the same procedures based on phylogenetic incongruence used to 
detect intergenotypic recombinants are applied to the detection of intragenotype and intersubtype RFs 
(Table 1). Until now, only five such cases have been described, four involving subtypes of genotype 1 
and one involving subtypes of genotype 4. The geographic distribution of these RFs is also very wide 
and the same applies to the locations of the inferred breakpoints. 
Interestingly, only two of the intersubtypic RFs have been fully sequenced [34,35] and, besides 
involving the same subtypes (1a and 1c), both include more than one breakpoint, resulting in mosaic 
patterns of recombination with portions corresponding to one subtype alternating with portions of 
another. Also, in both cases, these stretches are very dissimilar in size with one or a few relatively 
short segments of one subtype punctuating a genome of mostly the other subtype. There has been no 
detailed characterization of the nearby regions of the corresponding genomes and, as a result, no 
mechanism for the origin of these RFs has been put forward. 
The other three cases of intersubtypic RFs have been characterized only partially at the genome 
level. One case was described recently by discordant phylogenetic assignment of the HCV E1- and 
NS5B-gene sequences obtained from an IDU patient from Portugal [36]. Simultaneous infection with 
two strains of different HCV subtypes was not fully discarded and no recombination breakpoint(s) has 
been proposed for this RF, which has to be considered only as a putative case awaiting further 
characterization. The two remaining cases of intersubtypic recombination have been described by the 
same research group [37,38] after sequencing one single stretch of the HCV genome in which the 
corresponding breakpoints were identified. The genes involved, core and NS5B, are relatively 
conserved and, in fact, are normally used for the phylogenetic typing and subtyping of HCV isolates. 
In consequence, a large number of sequences for these two regions are available in public databases, 
although only a small fraction of them were used in the corresponding analyses. In addition, the 
sequences used do not encompass the actual levels of genetic variation at the intrasubtype level of 
these regions. Insufficient or unbiased sampling of control sequences may provide artifactual support 
for recombinant strains, especially when only small regions and a few sequences are used to obtain the 
phylogenetic trees from which recombination is inferred. Viruses 2011, 3 
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Table 1. Summary and main features of the published cases of recombination in Hepatitis C virus (HCV). The phylogenetic analyses column 
summarizes the method used for inferring the phylogenetic trees (NJ: neighbor-joining, ML: maximum likelihood), along with the 
evolutionary model (K2P: Kimura 2 parameter, TN: Tamura-Nei; GTR: general time reversible, G: gamma distribution for heterogeneity 
among sites), method for evaluating branch support (boot: bootstrap resampling with number of pseudorandom replicates, aLRT: approximate 
likelihood ratio test), and method or software used for testing and/or identifying recombination breakpoints. 
Strain  Genotype  Country  Recombination breakpoint(s)  Phylogenetic analyses  Refs. 
Intergenotype           
RFl_2k/1b  2k/1b  Russia, Ireland, 
Uzbekistan, 
Georgia/France, 
Cyprus 
NS2, positions 3175-3176  NJ-??-?boot; Simplot, Bootscan  [26,29–32] 
D3  2i/6p  Vietnam   NS2/NS3 junction, between positions 3405 
and 3464 
NJ-K2P-1000boot; Simplot, Bootscan  [39] 
SE-03-07-1689  RF3_2b/1b  Philippines  NS3, positions 3466-3467  NJ-??-?boot (CLUSTALW); Similarity plot (RAT)  [40] 
Rl  2/5  France  NS2/NS3 junction, between residues 3420 
and 3440 
NJ-TN+G-100boot(MEGA); RDP  [41] 
D177  RF_2b/6w  Taiwan  NS2/NS3 junction, position 3429  NJ-K2P-1000boot,Simplot  [33] 
  RF_3a/1b  Taiwan  undetermined  NJ-K2P-1000boot,Simplot  [33] 
  RF_2a/1a  Taiwan  undetermined  NJ-K2P-1000boot,Simplot  [33] 
HC10-0804  2b/1b  Japan  NS2/NS3 junction, positions 3443-3444  NJ-K2P-1000boot,Simplot and Bootscan   [42] 
JF779679  2b/1a  USA  NS2/NS3 junction, positions 3405-3416  NJ-??-?boot (CLUSTALW); Simplot  [43] 
Intersubtype  Subtypes         
PE22  RF2_1b/1a  Peru  NS5B, position 8321  NJ-K2P-1000boot (MEGA); Simplot, LARD  [37] 
HC-J1  1a/1c  Japan  2 sites in E1–E2, at positions 1407 and 2050  No PhylTree; Simplot, Bootscan  [34] 
Khajal  1a/1c  India  5 sites, from core to NS3, at positions 801, 
1261, 2181, 3041, and 3781 
ML(Modeltest), 5000 boot (NJ); Simplot, Bootscan  [35] 
H23  1b/1a  Uruguay  core, at position 387  ML-GTR+G, aLRT (Phyml); GARD, LARD  [38] 
R49  4a/4d  Portugal  undetermined  NJ-K2P-1000boot  [36] 
Intrapatient  Subtype         
  1b  Spain  NS5B, at the residue 286  No PhylTree; Simplot, Bootscan  [44] 
  1a, 1b, 3a  Spain  1 or 2 sites within E1E2 or NS5A  ML, GTR+G, 1000boot (Phyml); RDP3 (at least 
3+); SH + ELW (TreePuzzle) 
[45] 
 Viruses 2011, 3 
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Two additional reports of recombination in HCV have been published to date. Both involve 
intrapatient recombination of viruses circulating in individual patients undergoing therapy [44,45]. The 
first report partially analyzed a previously published data set [46] in which clone sequences were 
obtained at different times from the start of interferon+ribavirin therapy in search of escape mutations. 
HCV-RNA was isolated and RT-PCR products of the NS5A region were cloned and sequenced. In 
total, Moreno et al. analyzed 554 sequences that were sampled in weeks 0, 1, 2 and 4 from the start of 
the therapy in 6 of the 18 patients in the original paper by Puig-Basagoiti et al. [46]. The recombinant 
clone was found in a sustained responder patient and it corresponded to a sequence obtained in week 4 
of therapy with putative parental sequences obtained in weeks 0 and 1  [44]. The recombination 
breakpoint was located in the PKR-binding region of ISDR (Interferon Sensitivity Determining 
Region), a portion in the NS5A putatively linked to sensitivity to interferon-based therapy (although 
this issue remains highly controversial). In this work, the authors reported in detail only the results of 
the positive case, in which apparently only four sequences were actually compared. Failure to consider 
the whole spectrum of variability in the population may create an artifactual view of recombination, as 
previously commented, and this possibility should be taken into account because further analyses 
reveal that other clones, with identical nucleotide sequences to the one identified as recombinant, were 
not identified as such. 
Sentandreu et al. [45] analyzed over 17,700 sequences from two HCV genome regions, namely the 
E1-E2 region, encompassing hypervariable regions HVR1-HVR3, and a portion of NS5A, also 
including the ISDR. These sequences were obtained after cloning RT-PCR products of HCV-RNA 
obtained from 111 patients undergoing interferon+ribavirin therapy. No post-treatment sequences from 
sustained responders were available for study. The set of sequences from each patient was analyzed 
independently using the RDP3 software [47] and putative recombination events were considered only 
when at least three different methods concurred in identifying the same event. Further verification by 
maximum likelihood testing of each event led us to propose 43 recombination events from 17 different 
patients in the E1-E2 region, and 20 events from 9 patients in the NS5A region. The breakpoints 
proposed for each region were not distributed at random along the  sequences but appeared to 
concentrate at specific areas. Although no structural analyses were performed in this study, these 
results are congruent with the involvement of RNA secondary structure in facilitating, if not 
determining, the hotspots or zones where recombination can occur within the HCV genome. 
Finally, some additional cases of non-natural recombination in HCV have been published. For 
instance, Gao et al. [48] reported the detection of recombination in several experimentally-infected 
chimpanzees. Three chimpanzees were infected with HCV subtypes 1a and 1b simultaneously. The 
authors looked for HCV recombination by cloning and sequencing PCR fragments derived from the 
E1–E2 region. Recombination between subtypes 1a and 1b was found in two animals and they differed 
in the location of predicted breakpoint and order of subtype sequences. Recently, Reiter et al. [49] 
have analyzed the production of HCV recombinants in a replicon-based system with two marker 
mutations. Recombination in hepatic cell lines was necessary to restore the normal phenotype. In this 
experiment, recombination frequencies correlated with the distance between mutations and they were 
found to occur at a frequency of 4 × 10
−8 per nucleotide. Viruses 2011, 3 
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3. Negative Reports of Recombination 
Negative results are seldom published in scientific journals. Nevertheless, when they accumulate, 
they can be very informative and should be considered at least as indicators of an intrinsic difficulty in 
documenting the corresponding phenomenon. In consequence, before considering in more detail why it 
is apparently so difficult to document the existence of recombination in HCV, let us briefly consider a 
sample of negative reports after active searching.  
Most negative reports of recombination in HCV are published as complementary analysis when a 
new HCV subtype is characterized. These analyses became practically the norm once the RF1_2k/1b 
was initially described [26,28]. For instance, Bernardin et al. [50] failed to detect any recombinant 
genome after fully sequencing HCV isolates from 3 HCV-double infected patients (two cases were 1a 
followed by a different 1a strain, and the others were 3a followed by 1a, 1a followed by 3a, and 1b 
followed by 1a). However, only one genome was analyzed from each patient, thus reducing the 
chances of detecting any recombination should there be. 
Hmaied et al. [51] did not find evidence of recombination in the complete genomes of the two 
strains used to define subtype 4f. The same negative result was obtained by Bracho and coworkers in 
their analysis of subtype 1g [52]  and another, yet unnamed, subtype of genotype 1 [53], by   
Martró et al. [54] in the description of subtype 2q, and by Gupte et al. [55] in their analysis of novel 
subtype 3i and an Indian variant of subtype 3a. Kuntzen et al.  [56]  did not find evidence of 
recombination when they first analyzed complete sequences of subtype 4k in addition to five new 
sequences of subtypes 4d and 4f. 
Similarity analysis showed no evidence of inter- or intrasubtype recombination in the first complete 
genomes for subtypes 6c, 6l, 6o, 6p and 6q; corresponding to five HCV complete genome sequences 
from a blood donor in Thailand, and three Asian immigrants and one Caucasian in North 
America [57]. 
Viazov  et al.  [58]  actively searched for recombination and coinfection with different HCV 
genotypes in two highly exposed populations of IDUs in Russia (n = 47) and Germany (n = 118). Only 
two cases of recombination, as deduced from discordant sequence-based subtyping in core and NS5B 
regions, were detected. Both corresponded to 2k/1b recombinants of Russian origin. Furthermore, only 
one case of mixed infection (a 1a/3a combination) was identified, which led the authors to conclude 
that the actual prevalence of recombinant HCV viruses and the necessary previous step of co-infection, 
at least with different genotypes, are very rare even in these highly exposed settings. 
Magiorkinis et al. [59] performed a detailed analysis of full-length genome sequences of all HCV 
genotypes and subtypes available at that time. From their study, they concluded that there was no 
evidence for ancient recombination events with one possible, but yet unconfirmed, exception. This was 
derived from the analysis of genotype 4, for which one region (4195–4645) consistently inferred a 
different topology than the one proposed from the full length sequence, suggesting a strong 
monophyletic relationship with genotype 6. Given the ancient, close relationship between HCV 
genotypes 1 and 4, Magiorkinis et al. argue that the most probable reason for this observation is an 
ancient recombination event between ancestral strains of genotypes 1 and 6.  Viruses 2011, 3 
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4. Why Is Recombination in HCV so Difficult to Detect? 
The identification of several recombinant strains (Table 1) demonstrates that HCV is capable of 
successfully completing all the stages in the process: Simultaneous  infection of the same cell by 
different viral strains, simultaneous replication of both viral genomes, template shift by the viral RNA 
polymerase while keeping the correct reading frame, and encapsidation and release of the recombinant 
genomes. The resulting products will then be subjected to the same population processes governing the 
maintenance, expansion or disappearance of new variants in a heterogeneous viral population. We 
have already indicated that at least RF1_2k/1b has been found circulating in different countries. If 
recombination in HCV is not impossible then, why is it so uncommon? We next consider several 
points that may, at least partially, explain why HCV recombination is so rarely detected. 
One prerequisite for the production and detection of recombinant HCV is the simultaneous infection 
of the same cell by two parental viruses which differ sufficiently in their nucleotide sequences for a 
recombinant between them to be identified, usually through phylogenetic analysis. Previous 
reports [27] have shown superinfection exclusion (or homologous interference) in experimental cell 
cultures infected with HCV. This process implies that an HCV-infected cell becomes refractory to 
subsequent infection, thus severely limiting the possibility of recombination because the presence of 
two different viruses in the same cell after a secondary infection is prevented. However, the detection 
of intertype and intersubtype recombinant forms casts doubts on the validity of the previous 
conclusion, at least for natural infections, and indicates that simultaneous infection of the same cell by 
different HCVs, if not frequent, is at least possible, perhaps when the infection with the two strains is 
simultaneous. In fact, in cell-culture, simultaneous infection and co-replication of both viral genomes 
in the same cell has been detected, but when infections are performed sequentially, secondary infection 
is severely impaired [60]. 
A pre-requisite for simultaneous cell infection is that the individual is also infected by different 
viruses and this can be analyzed more easily than the more stringent condition of cell coinfection. 
Pham et al. [61] studied the prevalence of multiple infections (mixed infections, superinfections and 
reinfections) among IDUs in a prison setting and found by sequencing that 22 of 87 (25.3%) of the 
infected individuals with detectable HCV-RNA had two or more different virus strains. Lee et al. [33] 
analyzed the prevalence of double and triple infections among IDUs in different regions of Taiwan. 
They found that 14% and 1.3%, respectively, of 150 individuals analyzed carried viruses from two or 
three different HCV subtypes. Other reports on the prevalence of multiple HCV infection indicate 
values between 5% [62] and 39% [63]. Unfortunately, there are no reports on the frequency nor the 
type of cells simultaneously infected with two (or more) HCV subtypes in vivo, and the previous cases 
of coinfection at the organism level do not necessarily imply coinfection at the cellular level, although 
this is likely to occur given the previously described cases of recombination.  
Most routine genotyping analyses of HCV are based on a single or only two small genome regions 
and do not require determining its nucleotide sequence [64]. Recombination in viruses can only be 
confirmed after a detailed and rigorous analysis of the patterns of variation found at the nucleotide 
level (see below), using good reference data sets and stringent statistical criteria that can differentiate 
clearly between a true recombination event and the accumulation of independent mutations that mimic Viruses 2011, 3 
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the same final result expected after recombination. This is especially delicate and necessary for highly 
variable RNA viruses such as HCV.  
Despite recent improvements in algorithms and computer power, the detection of recombination is 
often limited by computation. Some popular programs aimed at identifying recombination in 
nucleotide sequences are still rather limited in the amount of data they can process at a time. In 
consequence, researchers are often tempted to trim the data sets to be analyzed so they can be 
processed in reasonable times. However, this may lead to wrong conclusions because the reduction of 
data may create an artificial appearance of alternating similarity/dissimilarity patterns, subsequently 
assigned to different parental sequences, when in fact a more or less continuum spectrum of variants 
does exist. One such case is the likely reason for a report of intratype recombination involving 
subtypes 1a and 1b [38].  
Alternatively, other authors have searched for methods with less demanding computational needs. 
For instance, Mes and van Doornum [65]  have compared two different approaches for inferring 
recombination in the dominant and minority subtypes of HCV genotype 1. They  used multiple 
alignments of partial or complete genome sequences, as available, and searched for signatures of 
recombination using the set of methods implemented in RDP3 [47] and the population genetic method 
developed by Betrán et al. [66]. The results obtained were markedly different with the two approaches. 
Although the phylogenetic methods implemented in RDP3 failed to detect any evidence for 
recombination, the population estimator of Betrán et al. revealed a large number of gene-conversion 
tracts. However, this result should be taken cautiously because Betrán et al.’s method was originally 
designed for detecting gene conversion in eukaryotes and its suitability and robustness when applied to 
rapidly varying genomes, such as those of RNA viruses like HCV, remains to be checked. The method 
relies heavily on the unlikelihood of simultaneous and independent occurrence of mutations, an 
assumption which is violated in HCV. 
To sum up, although it is certain that HCV is able to fulfill all the required steps for the production 
of recombinant genomes with parentals of a wide range of divergence, it is also true that different 
barriers for their production and detection have been described. Their nature prevents us from 
obtaining a reliable estimate of the global frequency of recombination in HCV. Furthermore, it is not 
possible to evaluate whether the cases currently described are truly representative of the actual levels 
of recombination in this virus or if they represent the tip of a large, unappreciated iceberg. 
5. Are Incongruent Trees Enough Evidence for Recombination? 
Phylogenetic trees are an essential tool in the identification and characterization of recombination 
events in viruses. Although the term ‘recombination’ has become the standard for denoting the 
mechanism by which a genome with chimeric portions of separate genealogical or phylogenetic origin 
is formed, the actual process is closer to what geneticists usually describe as ‘gene conversion’. There 
are important differences at the molecular level between both processes but, in their results, the main 
difference is that gene conversion is asymmetric: usually only one offspring genome is a chimera of 
two parental genomes, which continue producing identical, clonal offspring sequences unless a 
separate “recombination event” takes place. In consequence, the identification of a recombinant 
genome requires that at least two portions of it can be traced back to different most recent common Viruses 2011, 3 
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ancestors. This is only possible by phylogenetic  reconstruction and, as expected, the specific 
procedures used for it play a key role in the validity of the conclusions. The ensuing considerations are 
valid not just for HCV but for most other viruses and, in general, organisms in which recombination 
has to be inferred from the different ancestry of portions of their genome. 
Phylogenetic reconstruction is not an easy task, despite the recent development of user-friendly 
programs and packages for completing it. Many papers are published every year with a phylogenetic 
tree in which the authors are not aware of the intricacies and subtleties of the methods and choices they 
have applied, most often because they correspond to the default values in the programs or because they 
have followed the methods described in previous papers of similar contents or approaches. These are 
usually very bad choices and many published results would probably not hold once rigorous 
phylogenetic analyses are applied. There is only one possible way to work around this problem: to 
study seriously how and when to apply the different methods and to check that the data to be analyzed 
really fit the underlying, although often unstated, assumptions. 
Our goal here is not to review the different methods and assumptions of phylogenetic 
reconstructions with viral sequences, for which several excellent resources are available. Instead, we 
will concentrate on a few specific points which are often skipped in the analysis of viral sequences, in 
general, and in the identification of HCV recombination, in particular. 
Phylogenetic reconstruction is based on the analysis of shared character states resulting from 
common ancestry (homologies) and not from independent evolution (analogies). The first step in a 
phylogenetic analysis is, consequently, the establishment of the homology relationships among the 
different units (usually partial or complete genome sequences) to be compared. For nucleotide or 
amino acid sequences, this corresponds to their multiple alignment. Although multiple sequence 
alignments (MSAs) are usually straightforward for closely related sequences, hypervariable regions, 
especially those in which insertion/deletion events contribute significant variability, may be difficult to 
align. Occasionally it is preferable to remove poorly aligned portions (gblocks, [67]; trimal, [68]) than 
to derive wrong phylogenetic trees from an unreliable alignment. Protein coding regions should always 
be aligned using the derived amino acid sequences. There are two main reasons for this. First, it is this 
alignment which makes biological sense as indels introduced in the amino acid MSA will be ‘back-
translated’ correctly into the corresponding nucleotide MSA. Tools for doing this are available even in 
popular phylogenetic analysis programs such as MEGA [69]. Secondly, the actual algorithms used for 
deriving the MSA work much more efficiently on a 20-letter than on a 4-letter alphabet, thus 
facilitating their task. There are a plethora of methods for MSA and interested readers should consult 
some of the excellent recent reviews on this topic to gain more information [70–72]. For untranslated 
regions (UTRs), the secondary structure of RNA should also be considered as an essential component 
of the homology relationships to be ascertained [73,74]. 
Once a satisfying MSA has been obtained, it is necessary to ascertain whether the data hold enough 
phylogenetic information to allow the reconstruction of their evolutionary history confidently. Lack of 
information can be due to an excess or to a defect of nucleotide substitutions. In the former case, too 
many changes may remain unaccounted for, even after applying sophisticated models of evolutionary 
change, and some sequences may enter into the “Felsenstein zone”, a region in which sequences 
appear to be similar because of the independent accumulation of identical changes (homoplasies) and 
not because of a shared evolutionary history, leading to the well-known artifact of “long-branch Viruses 2011, 3 
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attraction”. This situation may arise when fast-evolving regions are used for phylogenetic 
reconstructions of sequences which shared a common ancestor a long time ago. In this case, the 
inferred phylogenetic tree does not correspond to the actual genealogical relationships of the 
corresponding sequences. A similar outcome can result when the number of nucleotide substitutions is 
very small, a typical situation in cases of very recent divergence from the common ancestor, especially 
when conserved or slowly-evolving genome regions are used in evolutionary inference. In these cases, 
a single homoplasy can artificially create groups of apparently shared ancestry but usually with a low 
bootstrap support. There are a few tools available for diagnosing these problems. One of the most 
popular methods is likelihood-mapping  [75], a maximum likelihood implementation of quartet 
analysis [76] in which 4-taxa subsets of the MSA are used to compare the three possible unrooted 
trees. The total proportion of well-resolved quartets, those in which one tree is significantly better than 
the others, provides an estimate of the global phylogenetic signal in the MSA. When this analysis 
identifies a poor-signal MSA, no firm conclusions should be derived from it. 
The next step in the phylogenetic analysis is to decide which method to use and, for those based on 
models of nucleotide or amino acid substitutions, to ascertain the best fitting model for the data. 
Although parsimony- and distance-based algorithms for phylogenetic reconstruction were favored for 
many years, recent developments in algorithms and computation power have allowed the 
popularization of maximum-likelihood and Bayesian-based approaches. The availability of more   
user-friendly software, although still requiring much more effort than simply “load the data and run”, 
is also helping to spread these methods which provide not only best evaluations of phylogenetic 
relationships for large datasets but also include a strong statistical background on which posterior 
analyses are based. As previously noted, this is not an adequate place to review this topic and the 
interested reader is referred to specific literature. Much the same can be said about the selection of 
evolutionary models. Fortunately, software developed by David Posada and his group allows for a 
relatively easy and straightforward evaluation of many of the most common, albeit simple, models for 
sequence evolution both at the nucleotide (jModeltest, [77]) and amino acid (ProtTest; [78]) levels. 
The relevance of using an appropriate evolutionary model in the inference of viral phylogenies was 
stressed by Posada & Crandall [79] and should be constantly taken into account. 
Once these points have been considered, there is still one final step to take before accepting that two 
non-congruent phylogenetic trees represent a clear proof of a recombination event. Two different 
phylogenies may represent different phylogenetic histories that, for a certain dataset, do not differ 
(significantly) in statistical support, or they might be the result of analytical artifacts. The statistical 
support for the different phylogenies (which are nothing but different hypotheses about the evolution 
of the corresponding genome fragments) has to be evaluated and there are several methods for doing it. 
The most popular methods (SH, [80]; ELW, [81]) have been developed under a likelihood framework 
and involve the comparison of the likelihood of the different trees for each multiple alignment. The 
main factors which can lead to misleading tree inferences include (1) long-branch attraction,   
(2) composition bias of nucleotide and amino acid, and (3) convergent evolution. The two former 
factors are unlikely to operate within a species, but the third one should be considered cautiously in the 
analysis of RNA virus recombination. Viruses 2011, 3 
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6. Implications of Recombination in HCV 
If there are not so many cases of recombination in HCV, why should we care about detecting and 
documenting them? There is, naturally, a genuine scientific interest in improving our knowledge of  
an important pathogen, from its evolution, epidemiology, natural history, replication, functional 
biology,  etc., all of which can be better understood from the analysis of natural and artificial 
recombinants. But a better knowledge of a pathogen should also be translated into practical applications. 
We have previously mentioned that HCV is currently classified into several genotypes and 
subtypes. This classification is based on phylogenetic analysis of complete or partial genome 
sequences [8]. However, in clinical practice, HCV is usually typed by one of several commercial kits 
available which are aimed at detecting genotype- or subtype-specific mutations in conserved regions of 
the genome [64]. These typing tests target only one, or at the most two, small regions in the genome 
and, in consequence, cannot be used to detect recombinant strains. Furthermore, occasional mutations 
in those specific sites may lead to wrong typing of HCV strains. This is relevant from a clinical point 
of view because prognosis, natural history, and treatment recommendations as well as viral response 
may differ between HCV genotypes. Some genotypes, such as genotypes 2 and 3, are usually linked to 
better prognosis and response to standard interferon-based treatment, whereas others are linked to 
higher rates of treatment failure, such as genotypes 1 and 4. HCV genotype is currently included in the 
routine clinical evaluation for treating HCV chronic infection. 
It is evident that recombinant strains may render at least some of these typing methods almost 
useless. In fact, Morel et al. [82] have recently advocated for new typing schemes for HCV based on at 
least two genome regions well apart in the viral genome (for instance, the 5'-UTR and NS5B gene). 
These tests should be carried out routinely as they would allow an easy identification of potential 
recombinants of different genotypes and even subtypes. As an additional precaution, these authors also 
propose the analysis of sequences of these or other similar regions when the expected response to 
therapy is not attained. 
However, a new era of therapeutics against HCV is just starting and the new antivirals are targeted 
against specific regions or positions of the HCV genome or proteome. Just as in many other RNA 
viruses, natural resistance variants in the HCV genome that allow the virus to avoid the effects of these 
drugs are already known [83,84] and the widespread use of these new treatments will eventually 
increase the number and frequency of resistance mutations. One of the basic strategies for preventing 
the spread of these variants and ultimately attaining the goal of eliminating or at least controlling the 
infecting virus below certain thresholds, is to simultaneously treat with drugs targeted to different 
proteins. The aim is to reduce the chances of resistance mutations simultaneously arising in the same 
individual genome that allow the corresponding viral particle to spread because its offspring can 
survive the antiviral drug selection. In these cases, recombination can act as a catalyst for antiviral 
resistance because it is no longer necessary that the two escape mutations arise simultaneously   
in the same genome;  they can be brought together as a result of recombination between the   
appropriate parentals. Consequently, a more intense surveillance of recombination in HCV is 
necessary to accommodate future therapeutics to prevent, or at least limit, the appearance and spread 
of resistance mutations. Viruses 2011, 3 
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A final implication of HCV recombination is the relevance from epidemiological and public health 
perspectives. In most countries, hepatitis C is a disease of mandatory communication to public health 
authorities. Given the high transmissibility of this virus and the important personal and social 
consequences of its infection, many countries have implemented an active surveillance of the main 
circulating genotypes and subtypes of HCV. This information is very valuable from an 
epidemiological point of view and recombination, for the same reasons indicated above, can mislead 
the basic information on the virus types found in a given population. 
7. Conclusions 
Recombination in HCV is still a rare event and the number of well-documented cases is still very 
low. There are difficulties at different levels for the production and detection of recombinant strains of 
this virus and, although there is still much uncertainty about its actual incidence, it is likely that the 
levels of recombination in HCV are being underestimated. This may have important practical 
consequences in the clinical and epidemiological settings, especially with the introduction of new 
therapeutic drugs for which specific resistance mutations are already known. Recombination can 
eventually facilitate combination of single resistance mutations in the same genome, and active 
epidemiological surveillance of recombinant forms will be of public health interest. 
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